AUTL

AUTOLUS THERAPEUTICS PLC

1.620

-0.040-2.42%

Opening11:02 06/24 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE1.660/1.660

TODAY RANGE1.590-1.680

VOL366.79K

MARKET CAP431.15M

52 WEEK RANGE1.175-2.700

AVG VOL (3M)1.57M

% TURNOVER0.14%

TURNOVER--

P/E (TTM)-1.4920

% RANGE5.42%

EPS(TTM)-1.0857

P/E(FORWARD)0.1002

P/B1.390

BVPS1.302

DIVIDEND--

P/S41.80

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP312.80M

SHARES OUTSTANDING266.16M

NEXT EARNINGS08/10-08/14

FREE FLOAT193.10M

LOT SIZE1

EX-DATE--

News

Press Releases

Financial Reports

Profile

NASDAQ·1d ago
Tango Appoints Robert Azelby To Board Of Directors
TipRanks·06/10 16:30
Analysts Have Conflicting Sentiments on These Healthcare Companies: Autolus Therapeutics (AUTL), Galmed Pharmaceuticals (GLMD) and Oculis Holding (OCS)
TipRanks·06/09 12:03
Autolus Schedules 2026 AGM and Engages ADS Holders
TipRanks·06/03 00:20
Analysts Are Bullish on Top Healthcare Stocks: Autolus Therapeutics (AUTL), Wuxi Biologics (Cayman) (WXIBF)
TipRanks·05/19 00:01
Autolus Therapeutics Signals Turning Point in Earnings
TipRanks·05/15 11:12
Wells Fargo Remains a Buy on Autolus Therapeutics (AUTL)
TipRanks·05/15 06:56
Goldman Sachs Sticks to Their Buy Rating for Autolus Therapeutics (AUTL)
Seeking Alpha·05/15 00:11
Autolus reiterates $120M-$135M 2026 AUCATZYL revenue guidance as it targets 65%-70% peak ALL gross margin
TipRanks·05/14 18:55
Autolus Therapeutics: Buy Rating Reiterated as Aucatzyl Momentum Builds and Pipeline Advances; $10 Price Target Maintained
TipRanks·05/14 18:55
Matt Phipps Reiterates Buy on Autolus as Aucatzyl’s Profitability Inflects and Blockbuster Potential Builds on Expanding Indications
TipRanks·05/14 18:12
Autolus Therapeutics price target raised to $10 from $9 at H.C. Wainwright
Dow Jones·05/14 17:45
Autolus Therapeutics Price Target Raised to $10.00/Share From $9.00 by HC Wainwright & Co.
Dow Jones·05/14 17:45
Autolus Therapeutics Is Maintained at Buy by HC Wainwright & Co.
TipRanks·05/14 12:45
Autolus Therapeutics reports Q1 EPS (27c), consensus (26c)
TipRanks·05/14 12:43
Autolus Therapeutics backs FY26 revenue view $120M-$135M, consensus $129.39M

Same Industry

Name/Symbol

Change%

Price

MCK

Biogen Inc

BIIB

-1.05%

196.58

AMGN

Shire

SHPG

0.00%

179.20

Bristol-Myers Squibb Company Celegne Contingent Value Rights

CELG-RT

-1.39%

0.1102

LLY

CELG

Therapeuticsmd Inc

TXMD

+2.56%

2.000

Johnson & Johnson

JNJ

-2.48%

228.39

ABBV

ZTS

Gilead Sciences Inc

GILD

-1.35%

123.76

Novo-Nordisk A/S

NVO

+6.61%

46.05

Bristol-Myers Squibb Co

BMY

-2.32%

54.00

Alexion Pharms

ALXN

+1.70%

182.50

Pfizer

PFE

-2.74%

25.21

SNY

GCVRZ

NVS

RDY

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.